Evidence map›Paper›PMID 28573176›Full record

ArticleEndoscopy international open2017

Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett's esophagus: a systematic review and meta-analysis.

Larissa L Fujii-Lau, Birtukan Cinnor, Nicholas Shaheen, Srinivas Gaddam, Srinadh Komanduri, V Raman Muthusamy, Ananya Das, Robert Wilson, Violette C Simon, Vladimir Kushnir and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endoscopy international open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05056051 (Additive Value of Wide-Area Transepithelial Sampling), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05056051 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Additive Value of Wide-Area Transepithelial Sampling (WATS3D) in Detection of Recurrence of Intestinal Metaplasia Following Endoscopic Eradication Therapy (EET) for Barrett's Esophagus-Related Neoplasia

TypeinterventionalSponsorNorthwestern UniversityRan2020 to 2025Enrolled200ConditionsBarrett Esophagus, Esophageal CancerArmsWATS-3D tissue sampling prior to forceps biopsies, WATS-3D tissue sampling following forceps biopsies
3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Review
  3. Optimized Surveillance Intervals Following Endoscopic Eradication of Dysplastic Barrett's Esophagus: An International Cohort Study.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Article
  4. Utility of ancillary studies in the diagnosis and risk assessment of Barrett's esophagus and dysplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. ENDOSCOPIC TREATMENT OF ESOPHAGEAL NEOPLASIA: A DECADE OF EVOLUTION.Transactions of the American Clinical and Climatological Association · 2020
    Article
  11. Review
  12. Article
  13. Durability of Endoscopic Treatment for Dysplastic Barrett's Esophagus.Current treatment options in gastroenterology · 2019
    Review
  14. Barrett's esophagus: novel strategies for screening and surveillance.Therapeutic advances in chronic disease · 2019
    Review
  15. Review
  16. Natural History of the Post-ablation Esophagus.Digestive diseases and sciences · 2018
    Review
  17. Review
  18. Update on the management of Barrett's esophagus in Austria.European surgery : ACA : Acta chirurgica Austriaca · 2017
    Article
  19. Article
  20. The evolution of endoscopic therapy for Barrett's esophagus.Therapeutic advances in gastrointestinal endoscopy
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Larissa L Fujii-LauWashington University School of Medicine, St. Louis, MO, USA.
Birtukan CinnorUniversity of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Nicholas ShaheenUniversity of North Carolina, Chapel Hill, NC, USA.
Srinivas GaddamWashington University School of Medicine, St. Louis, MO, USA.
Srinadh KomanduriFeinberg School of Medicine Northwestern University, Chicago, IL, USA.
V Raman MuthusamyUniversity of California, Los Angeles, Los Angeles, CA, USA.
Ananya DasArizona Center for Digestive Health, Gilbert, AZ, USA.
Robert WilsonUniversity of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Violette C SimonUniversity of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Vladimir KushnirWashington University School of Medicine, St. Louis, MO, USA.
Daniel MulladyWashington University School of Medicine, St. Louis, MO, USA.
Steven A EdmundowiczUniversity of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Dayna S EarlyWashington University School of Medicine, St. Louis, MO, USA.
Sachin WaniUniversity of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConflicting data exist with regard to recurrence rates of intestinal metaplasia (IM) and dysplasia after achieving complete eradication of intestinal metaplasia (CE-IM) in Barrett's esophagus (BE) patients.

aim(i) To determine the incidence of recurrent IM and dysplasia achieving CE-IM and (ii) to compare recurrence rates between treatment modalities [radiofrequency ablation (RFA) with or without endoscopic mucosal resection (EMR) vs stepwise complete EMR (SRER)].

methodsA systematic search was performed for studies reporting on outcomes and estimates of recurrence rates after achieving CE-IM. Pooled incidence [per 100-patient-years (PY)] and risk ratios with 95 %CI were obtained. Heterogeneity was measured using the

resultsA total of 39 studies were identified (25-RFA, 13-SRER, and 2 combined). The pooled incidence of any recurrence was 7.5 (95 %CI 6.1 - 9.0)/100 PY with a pooled incidence of IM recurrence rate of 4.8 (95 %CI 3.8 - 5.9)/100 PY, and dysplasia recurrence rate of 2.0 (95 %CI 1.5 - 2.5)/100 PY. Compared to the SRER group, the RFA group had significantly higher overall [8.6 (6.7 - 10.5)/100 PY vs. 5.1 (3.1 - 7)/100 PY,

conclusionThe results of this study demonstrate that the incidence rates of overall, IM, and dysplasia recurrence rates post-EET are not inconsiderable and reinforce the importance of close surveillance after achieving CE-IM.

Identifiers

PMID28573176
PMCPMC5451278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.